The role of PPARs in atherosclerosis

Trends in Molecular Medicine

Volumn 8, Issue 9, 2002, Pages 422-430

  Duval, Caroline ^a   Chinetti, Giulia ^a   Trottein, Francois ^b   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN SUBUNIT;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LIPID METABOLISM; LIPOPROTEIN METABOLISM; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

ACUTE-PHASE PROTEINS; ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL; HUMANS; INFLAMMATION; LEUKOCYTES; LIPID METABOLISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THROMBOSIS; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0036727448     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02385-7     Document Type: Review

References (101)

1. Atherosclerosis
2. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice
3. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
4. Activation of PPARδ alters lipid metabolism in db/db mice
5. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
6. Regulation of lipid and lipoprotein metabolism by PPAR activators
7. Peroxisome proliferator-activated receptor γ and metabolic disease
8. Role of peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells
9. Thiazolidinediones inhibit the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells
10. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
11. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated γ
12. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
13. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
14. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
15. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
16. PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells
17. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium
18. PPARγ agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression
19. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
20. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
21. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function
22. Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists regulate endothelial cell growth and secretion of vasoactive peptides
23. Hypertension and insulin resistance: Role of peroxisome proliferator-activated receptor γ
24. Nonhypoglycemic effects of thiazolidinediones
25. Oxidative stress as a regulator of gene expression in the vasculature
26. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
27. Inhibition of inducible nitric oxyde synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
28. Cell-mediated immunity in atherosclerosis
29. Dendritic cells and their involvement in atheroslcerosis
30. Lymphocytes are important in early atherosclerosis
31. IFN-γ potentiates atherosclerosis in ApoE knock-out mice
32. Peroxisome proliferator receptor γ activators inhibit interleukine-12 production in murine dendritic cells
33. Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells
34. The role of interleukine-12 in the development of atherosclerosis in ApoE-deficient mice
35. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses
36. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT
37. Inhibition of the transcription factors AP-1 and NF-κB in CD4 T cells by peroxisome proliferator-activated receptor γ ligands
38. The nuclear receptor PPARγ is expressed by mouse T lymphocytes and PPARγ agonists induce apoptosis
39. Nuclear receptor PPARα is expressed in resting murine lymphocytes: The PPARα in T and B lymphocytes is both transactivation and transrepression competent
40. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
41. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells
42. Oxidized low-density lipoprotein and peroxisome proliferator-activated receptor a down-regulate platelet-activating-factor receptor expression in human macrophages
43. PPARγ ligands inhibit TNF-α-induced lox-1 expression in cultured endothelial cells
44. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
45. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages
46. Identification of a peroxisome proliferator-activated receptor response element in the apolipoprotein E gene control region
47. Cloning of the human cholesteryl ester hydrolase promoter: Identification of functional peroxisomal proliferator-activated receptor responsive element
48. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages
49. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: Potential role of PPARs
50. Lipoprotein lipase, a key role in atherosclerosis?
51. Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages
52. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
53. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
54. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
55. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of PPARα activators
56. PPARα activators inhibit tissue factor expression and activity in human monocytes
57. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages
58. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells
59. Expression and function of PPARγ in rat and human vascular smooth muscle cells
60. Troglitazone, but not rosiglitazone, inhibit Na/H exchange activity and proliferation of macrovascular endothelial cells
61. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells
62. Troglitazone inhibits mitogenic signalling by insulin in vascular smooth muscle cells
63. Peroxisome proliferator-activated receptor γ ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration
64. Peroxisome proliferator-activated receptor γ activation inhibits interleukin-1β-mediated platelet-derived growth factor-α receptor gene expression via CCAAT/enhancer-binding protein-δ in vascular smooth muscle cells
65. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells
66. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
67. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells
68. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis
69. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression and macrophage accumulation in apolipoprotein E-deficient mice
70. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
71. Troglitazone, a PPARγ ligand, inhibit osteopontin gene expression in human monocyte/macrophage THP-1 cells
72. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
73. Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro
74. Apoptosis in atherosclerosis: Focus on oxidized lipids and inflammation
75. Apoptosis and related proteins in different stages of human atherosclerotic plaques
76. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia
77. Troglitazone upregulates nitric oxyde synthesis in vascular smooth muscle cells
78. Activation of peroxisome proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
79. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN
80. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions
81. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor γ
82. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2
83. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
84. Fibrates suppresss fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α
85. Negative regulation of human fibrinogen gene expression by PPARα agonists via inhibition of CCAAT box/enhancer binding protein β
86. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes
87. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
88. Troglitazone inhibits atherosclerosis in apolipoprotein E-knock-out mice: Pleiotropic effects on CD36 expression and HDL
89. Another potential use of troglitazone in non-insulin-dependent diabetes mellitus
90. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy
91. Effects of troglitazone on collagen accumulation and distensibilty of aortic wall in prestage of non-insulin-dependent diabete mellitus of Otsuka Long-Evans Tokushima fatty rats
92. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
93. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
94. Effects of troglitazone on frequency of coronary vasospatic-induced angina pectoris in patients with diabetes mellitus
95. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes
96. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus
97. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients
98. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
99. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
100. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
101. Macrophage expression of PPAR-α inhibits atherosclerotic lesion formation in LDL-receptor deficient mice